XML 70 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2024 and 2023 is as follows:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
Federal statutory income tax rate   21.00%   21.00%
State tax rate, net   5.58%   5.77%
Permanent differences   (0.04)%   (0.25)%
Federal orphan drug tax credit   0.05%   1.41%
Deferred tax asset valuation allowance   (26.59)%   (27.93)%
           
Effective income tax rate   0.00%   0.00%
Schedule of Deferred Tax Assets and Liabilities

The significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:

 

   2024   2023 
   December 31, 
   2024   2023 
Deferred tax assets:          
Non-current:          
Net operating loss carry forward – Federal  $7,566,071    $6,012,941 
Net operating loss carry forward – State   2,074,542     1,672,436 
Stock compensation expense   2,794,226    3,453,799 
Depreciation and other   238     999 
Purchased in-process R&D   2,477,193     2,500,562 
Federal orphan drug credits   1,209,202     1,202,955 
Capitalized research and development costs   3,781,193     2,795,379 
Start-up expenditures and amortization   -     - 
Total non-current deferred tax assets   19,902,665     17,639,071 
Valuation allowance for deferred tax assets   (19,902,665)   (17,639,071)
Total deferred tax assets   -    - 
           
Deferred Tax Liabilities:          
Non-current:          
Intangible asset   -    - 
Total non-current deferred tax liabilities   -    - 
           
Total deferred tax asset (liability)  $-   $-